ImmuPharma   Report issue

For profit Phase 3
Founded: Westminster United Kingdom (1999)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2015
NCT02504645
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

ImmuPharma

Active Ingredients

Drugs in Phase 3 Trials (1)

Rigerimod (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lupus Erythematosus, Systemic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1